메뉴 건너뛰기




Volumn 33, Issue 11, 2009, Pages

A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ARSENIC TRIOXIDE; CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; THALIDOMIDE;

EID: 68649104180     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.009     Document Type: Letter
Times cited : (2)

References (14)
  • 2
    • 33749438404 scopus 로고    scopus 로고
    • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    • List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
    • (2006) N Engl J Med , vol.355 , pp. 1456-1465
    • List, A.1    Dewald, G.2    Bennett, J.3    Giagounidis, A.4    Raza, A.5    Feldman, E.6
  • 4
    • 34247337635 scopus 로고    scopus 로고
    • Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion
    • Martin J., Andrea P., Ann-Mari F., Emma K.E., Mats M., Jan S., et al. Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion. Blood 106 (2005) 960a
    • (2005) Blood , vol.106
    • Martin, J.1    Andrea, P.2    Ann-Mari, F.3    Emma, K.E.4    Mats, M.5    Jan, S.6
  • 5
    • 23944489636 scopus 로고    scopus 로고
    • Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
    • Giagounidis A.A., Germing U., Strupp C., Hildebrandt B., Heinsch M., and Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 84 (2005) 569-571
    • (2005) Ann Hematol , vol.84 , pp. 569-571
    • Giagounidis, A.A.1    Germing, U.2    Strupp, C.3    Hildebrandt, B.4    Heinsch, M.5    Aul, C.6
  • 6
    • 38049113182 scopus 로고    scopus 로고
    • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
    • Raza A., Reeves J.A., Feldman E.J., Dewald G.W., Bennett J.M., Deeg H.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111 (2008) 86-93
    • (2008) Blood , vol.111 , pp. 86-93
    • Raza, A.1    Reeves, J.A.2    Feldman, E.J.3    Dewald, G.W.4    Bennett, J.M.5    Deeg, H.J.6
  • 7
    • 33748205495 scopus 로고    scopus 로고
    • International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    • Tefferi A., Barosi G., Mesa R.A., Cervantes F., Deeg H.J., Reilly J.T., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108 (2006) 1497-1503
    • (2006) Blood , vol.108 , pp. 1497-1503
    • Tefferi, A.1    Barosi, G.2    Mesa, R.A.3    Cervantes, F.4    Deeg, H.J.5    Reilly, J.T.6
  • 8
    • 65449150965 scopus 로고    scopus 로고
    • Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
    • Adès L., Boehrer S., Prebet T., Beyne-Rauzy O., Legros L., Ravoet C., et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 113 (2009) 3947-3952
    • (2009) Blood , vol.113 , pp. 3947-3952
    • Adès, L.1    Boehrer, S.2    Prebet, T.3    Beyne-Rauzy, O.4    Legros, L.5    Ravoet, C.6
  • 9
    • 33845692628 scopus 로고    scopus 로고
    • Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
    • Giagounidis A.A., Haase S., Heinsch M., Gohring G., Schlegelberger B., and Aul C. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol 86 (2007) 133-137
    • (2007) Ann Hematol , vol.86 , pp. 133-137
    • Giagounidis, A.A.1    Haase, S.2    Heinsch, M.3    Gohring, G.4    Schlegelberger, B.5    Aul, C.6
  • 10
    • 33745961875 scopus 로고    scopus 로고
    • Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
    • Chang D.H., Liu N., Klimek V., Hassoun H., Mazumder A., Nimer S.D., et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108 (2006) 618-621
    • (2006) Blood , vol.108 , pp. 618-621
    • Chang, D.H.1    Liu, N.2    Klimek, V.3    Hassoun, H.4    Mazumder, A.5    Nimer, S.D.6
  • 11
    • 0033168605 scopus 로고    scopus 로고
    • Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
    • Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163 (1999) 380-386
    • (1999) J Immunol , vol.163 , pp. 380-386
    • Corral, L.G.1    Haslett, P.A.2    Muller, G.W.3    Chen, R.4    Wong, L.M.5    Ocampo, C.J.6
  • 12
    • 60849118093 scopus 로고    scopus 로고
    • Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality
    • Mesa R.A., Hanson C.A., Ketterling R.P., Schwager S., Knudson R.A., and Tefferi A. Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. Blood 113 (2009) 1200-1201
    • (2009) Blood , vol.113 , pp. 1200-1201
    • Mesa, R.A.1    Hanson, C.A.2    Ketterling, R.P.3    Schwager, S.4    Knudson, R.A.5    Tefferi, A.6
  • 13
    • 10744229499 scopus 로고    scopus 로고
    • Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
    • Giagounidis A.A., Germing U., Haase S., Hildebrandt B., Schlegelberger B., Schoch C., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18 (2004) 113-119
    • (2004) Leukemia , vol.18 , pp. 113-119
    • Giagounidis, A.A.1    Germing, U.2    Haase, S.3    Hildebrandt, B.4    Schlegelberger, B.5    Schoch, C.6
  • 14
    • 34848904494 scopus 로고    scopus 로고
    • Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation
    • Gupta R., Soupir C.P., Johari V., and Hasserjian R.P. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 139 (2007) 265-268
    • (2007) Br J Haematol , vol.139 , pp. 265-268
    • Gupta, R.1    Soupir, C.P.2    Johari, V.3    Hasserjian, R.P.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.